Innate lymphoid cells (ILC) are recently identified immune cells with a high cytokine-producing capacity at mucosal barriers. In patients with active CD, a shift is observed from homeostatic ILC3 towards pro-inflammatory ILC1 in the intestines. Ustekinumab – which targets the p40 subunit shared by IL-12 and IL-23 – was recently approved by the FDA and EMA for treatment of moderate-to-severe CD.
IL-12 and IL-23 play distinct roles in the plasticity of ILC1 and ILC3. Creyns et al. evaluated how biological therapy impacts ILC populations in peripheral blood by studying the effect of ustekinumab on ILC populations in blood .
A total of 46 CD patients (68% female; median age 42 years) was included. They were refractory to anti-tumour necrosis factor (TNF) therapy and vedolizumab with a median SES-CD of 16.5. Treatment initiated with ustekinumab (6 mg/kg intravenous (IV) at induction, followed by subcutaneous (SC) ustekinumab 90 mg q8w thereafter).<...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Higher colectomy rate with infliximab vs. conventional therapies in more severe UC Next Article
Vedolizumab in anti-TNF-naïve IBD patients and safety profile »